Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients

  • H. Palmedo
  • C. Marx
  • A. Ebert
  • B. Kreft
  • Y. Ko
  • A. Türler
  • R. Vorreuther
  • U. Göhring
  • H. H. Schild
  • T. Gerhardt
  • U. Pöge
  • S. Ezziddin
  • H.-J. Biersack
  • H. Ahmadzadehfar
Original Article

Abstract

Purpose

This study was designed to assess the additional value of SPECT/CT of the trunk used in conjunction with conventional nuclear imaging and its effects on patient management in a large patient series.

Methods

In 353 patients, whole-body scintigraphy (WBS), SPECT, and SPECT/CT were prospectively performed for staging and restaging. SPECT/CT of the trunk was performed in all patients. In the 308 evaluable patients (211 with breast cancer, 97 with prostate cancer), clinical follow-up was used as the gold standard. Bone metastases were confirmed in 72 patients and excluded in 236. Multistep analyses per lesion and per patient were performed. Clinical relevance was expressed in terms of downstaging and upstaging rates on a per-patient basis.

Results

In the total patient group, sensitivities, specificities, and negative and positive predictive values on a per-patient basis were 93 %, 78 %, 95 % and 59 % for WBS, 94 %, 71 %, 97 % and 53 % for SPECT, and 97 %, 94 %, 97 % and 88 % for SPECT/CT, respectively. In all subgroups, specificity and positive predictive value were significantly (p < 0.01) better with SPECT/CT. Downstaging of metastatic disease in the total, breast cancer and prostate cancer groups using SPECT/CT was possible in 32.1 %, 33.8 % and 29.5 % of patients, respectively. Upstaging in previously negative patients by additional SPECT/CT was observed in three breast cancer patients (2.1 %). Further diagnostic imaging procedures for unclear scintigraphic findings were necessary in only 2.5 % of patients. SPECT/CT improved diagnostic accuracy for defining the extent of multifocal metastatic disease in 34.6 % of these patients.

Conclusions

SPECT/CT significantly improved the specificity and positive predictive value of bone scintigraphy in cancer patients. In breast cancer patients, we found a slight increase in sensitivity. SPECT/CT had a significant effect on clinical management because of correct downstaging and upstaging, better definition of the extent of metastases, and a reduction in further diagnostic procedures.

Keywords

SPECT/CT Bone scintigraphy Bone metastases Prostate cancer Breast cancer 

Notes

Conflicts of interest

None.

References

  1. 1.
    Horger M, Eschmann SM, Pfannenberg C, Vonthein R, Besenfelder H, Claussen CD, et al. Evaluation of combined transmission and emission tomography for classification of skeletal lesions. AJR Am J Roentgenol. 2004;183(3):655–61.PubMedCrossRefGoogle Scholar
  2. 2.
    Nomayr A, Romer W, Strobel D, Bautz W, Kuwert T. Anatomical accuracy of hybrid SPECT/spiral CT in the lower spine. Nucl Med Commun. 2006;27(6):521–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Willowson K, Bailey DL, Baldock C. Quantitative SPECT reconstruction using CT-derived corrections. Phys Med Biol. 2008;53(12):3099–112.PubMedCrossRefGoogle Scholar
  4. 4.
    Reinartz P, Schaffeldt J, Sabri O, Zimny M, Nowak B, Ostwald E, et al. Benign versus malignant osseous lesions in the lumbar vertebrae: differentiation by means of bone SPET. Eur J Nucl Med. 2000;27(6):721–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Romer W, Nomayr A, Uder M, Bautz W, Kuwert T. SPECT-guided CT for evaluating foci of increased bone metabolism classified as indeterminate on SPECT in cancer patients. J Nucl Med. 2006;47(7):1102–6.PubMedGoogle Scholar
  6. 6.
    Utsunomiya D, Shiraishi S, Imuta M, Tomiguchi S, Kawanaka K, Morishita S, et al. Added value of SPECT/CT fusion in assessing suspected bone metastasis: comparison with scintigraphy alone and nonfused scintigraphy and CT. Radiology. 2006;238(1):264–71.PubMedCrossRefGoogle Scholar
  7. 7.
    Strobel K, Burger C, Seifert B, Husarik DB, Soyka JD, Hany TF. Characterization of focal bone lesions in the axial skeleton: performance of planar bone scintigraphy compared with SPECT and SPECT fused with CT. AJR Am J Roentgenol. 2007;188(5):W467–474.PubMedCrossRefGoogle Scholar
  8. 8.
    Helyar V, Mohan HK, Barwick T, Livieratos L, Gnanasegaran G, Clarke SE, et al. The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate. Eur J Nucl Med Mol Imaging. 2010;37(4):706–13.PubMedCrossRefGoogle Scholar
  9. 9.
    Zhao Z, Li L, Li F, Zhao L. Single photon emission computed tomography/spiral computed tomography fusion imaging for the diagnosis of bone metastasis in patients with known cancer. Skeletal Radiol. 2010;39(2):147–53.PubMedCrossRefGoogle Scholar
  10. 10.
    Sharma P, Kumar R, Singh H, Bal C, Julka PK, Thulkar S, et al. Indeterminate lesions on planar bone scintigraphy in lung cancer patients: SPECT, CT or SPECT-CT? Skeletal Radiol. 2012;41(7):843–50.PubMedCrossRefGoogle Scholar
  11. 11.
    Palmedo H, Bucerius J, Joe A, Strunk H, Hortling N, Meyka S, et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med. 2006;47(4):616–24.PubMedGoogle Scholar
  12. 12.
    Silvestri GA, Gould MK, Margolis ML, Tanoue LT, McCrory D, Toloza E, et al. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007;132(3 Suppl):178S–201S.PubMedCrossRefGoogle Scholar
  13. 13.
    Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol. 2004;171(6 Pt 1):2122–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Houssami N, Costelloe CM. Imaging bone metastases in breast cancer: evidence on comparative test accuracy. Ann Oncol. 2012;23(4):834–43.PubMedCrossRefGoogle Scholar
  15. 15.
    Schirrmeister H, Guhlmann A, Kotzerke J, Santjohanser C, Kühn T, Kreienberg R, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol. 1999;17(8):2381–9.PubMedGoogle Scholar
  16. 16.
    Schirrmeister H, Glatting G, Hetzel J, Nüssle K, Arslandemir C, Buck AK, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med. 2001;42(12):1800–4.PubMedGoogle Scholar
  17. 17.
    Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47(2):287–97.PubMedGoogle Scholar
  18. 18.
    Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31(5):578–83.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • H. Palmedo
    • 1
  • C. Marx
    • 2
  • A. Ebert
    • 1
  • B. Kreft
    • 1
  • Y. Ko
    • 4
  • A. Türler
    • 5
  • R. Vorreuther
    • 6
  • U. Göhring
    • 7
  • H. H. Schild
    • 2
  • T. Gerhardt
    • 8
  • U. Pöge
    • 8
  • S. Ezziddin
    • 3
  • H.-J. Biersack
    • 3
  • H. Ahmadzadehfar
    • 3
  1. 1.Institute of Radiology and Nuclear Medicine and PET-CT CenterJohanniter HospitalBonnGermany
  2. 2.Department of RadiologyUniversity HospitalBonnGermany
  3. 3.Department of Nuclear MedicineUniversity HospitalBonnGermany
  4. 4.Department of Internal Medicine/Clinical Cancer CenterJohanniter HospitalBonnGermany
  5. 5.Department of SurgeryJohanniter HospitalBonnGermany
  6. 6.Department of UrologyWaldkrankenhaus HospitalBonnGermany
  7. 7.Department of Obstetrics and GynecologyJohanniter HospitalBonnGermany
  8. 8.Institute of Internal Medicine/NephrologyBonnGermany

Personalised recommendations